HDM2 protein overexpression and prognosis in primary malignant melanoma Journal Article

  


Authors: Polsky, D.; Melzer, K.; Hazen, C.; Kamino, H.; Spira, J. G.; Kopf, A. W.; Perelman, R. O.; Osman, I.; Panageas, K. S.; Busam, K.; Drobnjak, M.; Cordon-Cardo, C.; Houghton, A.
Article Title: HDM2 protein overexpression and prognosis in primary malignant melanoma
Abstract: Overexpression of the oncogene HDM2 is observed in a substantial proportion of melanomas, including noninvasive and thin lesions, suggesting that HDM2 overexpression may be an early event in melanocyte transformation. To determine the role of HDM2 in the clinical progression of melanoma, we examined whether its expression was associated with patient survival. From November 1972 through November 1982, 134 patients with melanoma who participated in the New York University Melanoma Cooperative Group were studied, if representative tissues and follow-up were available. HDM2 protein expression was assessed immunohistochemically. Unexpectedly, we observed that HDM2 overexpression was statistically significantly associated with improved disease-free survival (relative risk [RR] = 0.47, 95% confidence interval [CI] = 0.24 to 0.89; two-sided X2 p =.021) and overall survival (RR = 0.55, 95% CI = 0.33 to 0.94; two-sided X2 P =.027) in multivariable analysis. HDM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospect' studies are required for validation.
Keywords: immunohistochemistry; adult; cancer survival; protein expression; aged; middle aged; unclassified drug; proto-oncogene proteins; cancer growth; protein function; gene overexpression; melanoma; skin neoplasms; melanocyte; neoplasm proteins; prediction; nuclear proteins; confidence interval; gene expression regulation, neoplastic; statistical significance; clinical study; multivariate analysis; neoplasm invasiveness; up-regulation; malignant transformation; protein mdm2; proto-oncogene proteins c-mdm2; humans; prognosis; human; male; female; priority journal; article
Journal Title: JNCI: Journal of the National Cancer Institute
Volume: 94
Issue: 23
ISSN: 0027-8874
Publisher: Oxford University Press  
Date Published: 2002-12-04
Start Page: 1803
End Page: 1806
Language: English
PUBMED: 12464652
PROVIDER: scopus
DOI: 10.1093/jnci/94.23.1803
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-0037021660&partnerID=40&md5=cd93b80433cd324e1850f12e3c4e035a
Notes: Export Date: 14 November 2014 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Carlos Cordon-Cardo
    612 Cordon-Cardo
  2. Katherine S Panageas
    512 Panageas
  3. Klaus J Busam
    688 Busam
  4. Alan N Houghton
    364 Houghton
  5. Marija Drobnjak
    61 Drobnjak
Related MSK Work